Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 97
- Registration Number
- NCT02374099
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇧🇪Clinique Sainte Elisabeth - Service d'Oncologie, Namur, Belgium
🇩🇪Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT02367196
- Locations
- 🇪🇸
Duran i Reynals Institut Catala d'Oncologia, Barcelona, Spain
🇺🇸Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States
🇪🇸Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 64
- Registration Number
- NCT02367183
- Locations
- 🇺🇸
Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 65
- Registration Number
- NCT02348528
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, China
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
- Conditions
- Lymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 59
- Registration Number
- NCT02343536
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- Other: N/A (non-interventional study)
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 120
- Registration Number
- NCT02342847
- Locations
- 🇪🇸
Hospital Universitario Burgos, Burgos, Castilla Y León, Spain
🇪🇸Complejo Asistencial León, León, Castilla Y León, Spain
🇪🇸Germans Trias i Pujol, Badalona, Cataluña, Spain
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
- Conditions
- Lymphoma, Mantle-Cell
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT02341781
- Locations
- 🇺🇸
University of Miami and Sylvester Comprehensive Cancer, Miami, Florida, United States
🇺🇸University of Michigan Comprehensive Cancer Center Division of Hematology Oncology, Ann Arbor, Michigan, United States
🇮🇹Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
- Conditions
- Malignant GliomaGlioblastoma
- Interventions
- Drug: MRZDrug: BEV
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 121
- Registration Number
- NCT02330562
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸University of Californai, Irvine, Orange, California, United States
🇨🇦Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT02323906
- Locations
- 🇺🇸
University of Florida College of Med, Gainesville, Florida, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT02321644
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
🇺🇸TKL Research, Fair Lawn, New Jersey, United States